Viking Therapeutics' Potential to Double in GLP-1 Race by 2030

Viking Therapeutics (NASDAQ: VKTX) is positioning itself at the heart of the rapidly expanding GLP-1 drug market. Over the past five years, the clinical-stage biotech has seen its stock surge over 500%, driven by advancements in pipeline candidates like VK2735 and VK3019, which target obesity and diabetes through novel mechanisms. With the GLP-1 market projected to reach $190 billion by 2035—up from $79 billion in 2023—Viking aims to carve out a differentiated niche amid dominance from Eli Lilly and Novo Nordisk. The company's subcutaneous VK2735, currently in Phase 3 trials, could complete development within 12-18 months and potentially secure regulatory approval by late 2028. However, clinical success alone may not guarantee investor returns; VK2735 must match or exceed the efficacy benchmarks set by Zepbound, the current market leader in obesity treatment. Additionally, Viking's strategy to combine VK2735 with VK3019—a dual amylin and calcitonin agonist—could offer a multi-pathway approach to obesity, potentially delivering superior outcomes. Beyond pharmaceuticals, this growth trajectory has implications for air freight and logistics. The surge in GLP-1 demand, particularly for temperature-sensitive and high-value pharmaceutical shipments, underscores the need for resilient supply chains and specialized cargo solutions. As biotech firms advance through clinical stages, logistics providers must scale capacity and adapt to stringent handling requirements. Viking's trajectory highlights how pharmaceutical innovation intersects with global logistics challenges, where precision and speed become competitive advantages.

Gökberk Uçar Note: The GLP-1 boom presents a logistics inflection point. Companies like Viking Therapeutics will require tailored air freight strategies for temperature-controlled, high-priority shipments. This trend could redefine cargo handling standards, especially for oral and injectable formulations. Aviation logistics must evolve to meet the dual demands of speed and compliance in pharmaceutical distribution.